

GENERAL CONFORMITY CERTIFICATE
Consumer Protection Safety Improvements Act (CPSIA)
15 U.S.C. § 2063(a)

The Manufacturer below certifies that the product identified below is in compliance with applicable CPSC-enforced safety rules.

1. Specific product covered by this certificate:

Soliqua™ 100/33 (insulin glargine and lixisenatide injection)
NDC # 00024-5761-05

2. Specific regulation(s), rules, bans, and/or standards for which this product is being certified:

16 CFR §§ 1700.14(a) & 1700.15

3. Manufacturer or importer certifying compliance:

Name: Sanofi US
Mailing address: 55 Corporate Drive, Bridgewater, NJ 08807
Telephone number: 1-800-372-6634

4. Individual maintaining records of the test results upon which this certification is based:

Name and/or title: Mark DeSieno
Sr. Director, Industrial Development, Industrial Affairs
55 Corporate Drive, Bridgewater, NJ 08807

For information contact:

Phone: 1-908-981-3922
Email: mark.desieno@sanofi.com

5. Date and place where this product was packaged:

Products are packaged at one or more locations. For information on the date and place of packaging of a specific product, please contact us at 1-800-372-6634 or TradeCustomerSupport@sanofi.com, with the Lot number and Expiration Date from the product container.

6. Date and place where this product was tested for compliance and third party laboratory(ies) that conducted testing upon which this certification is based.

Date of test reports: N/A

Name and Mailing Address of Testing Laboratory: N/A

If box is checked, then product testing requirements were not applicable



Approved: _____

Mark DeSieno

Date: _____

20 Sept. 2018

Sr. Director, Industrial Development, Industrial Affairs